Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma--a Nordic Lymphoma Group study

Research output: Contribution to journalJournal articleResearchpeer-review


  1. Inherited variation in the xenobiotic transporter pathway and survival of multiple myeloma patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. How do we move towards a personalised approach in the treatment of Early Hodgkin lymphoma?

    Research output: Contribution to journalEditorialResearchpeer-review

  1. Epigenetic therapy in hematological cancers

    Research output: Contribution to journalReviewResearchpeer-review

  2. Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Mother-child transmission of epigenetic information by tunable polymorphic imprinting

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Enzyme-free digital counting of endogenous circular RNA molecules in B-cell malignancies

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Mantle cell lymphoma (MCL) is an aggressive B cell lymphoma, where survival has been remarkably improved by use of protocols including high dose cytarabine, rituximab and autologous stem cell transplantation, such as the Nordic MCL2/3 protocols. In 2008, a MCL international prognostic index (MIPI) was created to enable stratification of the clinical diverse MCL patients into three risk groups. So far, use of the MIPI in clinical routine has been limited, as it has been shown that it inadequately separates low and intermediate risk group patients. To improve outcome and minimize treatment-related morbidity, additional parameters need to be evaluated to enable risk-adapted treatment selection. We have investigated the individual prognostic role of the MIPI and molecular markers including SOX11, TP53 (p53), MKI67 (Ki-67) and CCND1 (cyclin D1). Furthermore, we explored the possibility of creating an improved prognostic tool by combining the MIPI with information on molecular markers. SOX11 was shown to significantly add prognostic information to the MIPI, but in multivariate analysis TP53 was the only significant independent molecular marker. Based on these findings, we propose that TP53 and SOX11 should routinely be assessed and that a combined TP53/MIPI score may be used to guide treatment decisions.

Original languageEnglish
JournalBritish Journal of Haematology
Issue number1
Pages (from-to)98-108
Number of pages11
Publication statusPublished - Jul 2014

    Research areas

  • Adolescent, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Child, Cohort Studies, Cyclin D1, Female, Humans, Lymphoma, Mantle-Cell, Male, Neoplasm Proteins, Neoplasm Staging, Prognosis, SOXC Transcription Factors, Severity of Illness Index, Survival Analysis, Treatment Outcome, Tumor Markers, Biological, Tumor Suppressor Protein p53

ID: 44704987